X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (363) 363
humans (320) 320
male (190) 190
female (186) 186
animals (162) 162
middle aged (125) 125
pharmacology & pharmacy (117) 117
drug therapy, combination (109) 109
hepatitis c, chronic - drug therapy (105) 105
macrocyclic compounds - therapeutic use (102) 102
antiviral agents - therapeutic use (98) 98
uracil - analogs & derivatives (98) 98
adult (86) 86
hepacivirus - genetics (85) 85
aged (84) 84
hepatitis c virus (84) 84
carbamates - therapeutic use (80) 80
ribavirin (80) 80
genotype (79) 79
hepatitis c (78) 78
macrocyclic compounds - administration & dosage (76) 76
anilides - therapeutic use (72) 72
analysis (70) 70
macrocyclic compounds - adverse effects (70) 70
treatment outcome (69) 69
antiviral agents - adverse effects (67) 67
antiviral agents - administration & dosage (64) 64
ritonavir - therapeutic use (63) 63
sulfonamides - therapeutic use (63) 63
hepacivirus - drug effects (60) 60
carbamates - administration & dosage (59) 59
carbamates - adverse effects (58) 58
ritonavir (56) 56
gastroenterology & hepatology (55) 55
uracil - therapeutic use (54) 54
lactams, macrocyclic - pharmacology (52) 52
article (51) 51
health aspects (51) 51
anilides - administration & dosage (50) 50
anilides - adverse effects (50) 50
hsp90 heat-shock proteins - antagonists & inhibitors (50) 50
antiviral agents (49) 49
benzoquinones - pharmacology (48) 48
drug therapy (48) 48
hepatitis (48) 48
macrocyclic compounds - pharmacology (48) 48
mice (47) 47
ribavirin - therapeutic use (47) 47
sulfonamides - administration & dosage (47) 47
hcv (46) 46
ritonavir - administration & dosage (46) 46
sulfonamides - adverse effects (46) 46
ritonavir - adverse effects (45) 45
care and treatment (44) 44
heat shock proteins (44) 44
hepatitis c - drug therapy (44) 44
oncology (44) 44
research (43) 43
abt-450/r-ombitasvir (42) 42
cancer (42) 42
dose-response relationship, drug (42) 42
interferon (42) 42
pharmacokinetics (42) 42
in-vitro (41) 41
rats (41) 41
ivermectin (40) 40
uracil - administration & dosage (40) 40
macrocyclic lactones (38) 38
uracil - adverse effects (38) 38
biochemistry & molecular biology (37) 37
hepatitis c, chronic - virology (37) 37
macrocyclic compounds - chemistry (37) 37
dasabuvir (36) 36
sustained virologic response (36) 36
therapy (36) 36
toxicology (36) 36
young adult (36) 36
liver (35) 35
drug combinations (34) 34
antineoplastic agents - pharmacology (33) 33
cell line, tumor (33) 33
hsp90 (33) 33
macrocyclic compounds (33) 33
parasitology (33) 33
cirrhosis (32) 32
medicine & public health (32) 32
sustained virological response (32) 32
chemistry, medicinal (31) 31
genetic aspects (31) 31
infections (31) 31
infection (30) 30
macrocyclic compounds - pharmacokinetics (30) 30
ombitasvir (30) 30
patients (30) 30
clinical trials (29) 29
geldanamycin (29) 29
hsp90 heat-shock proteins - metabolism (29) 29
liver cirrhosis (29) 29
proteins (29) 29
sofosbuvir (29) 29
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2134 - 2146
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | VIRUS-INFECTION | TELAPREVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | COMBINATION | TRIAL | CIRRHOSIS | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin
Journal Article
Gastroenterology, ISSN 0016-5085, 2017, Volume 153, Issue 1, pp. 113 - 122
Background & Aims Patients with chronic hepatitis C virus (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of treatment... 
Gastroenterology and Hepatology | Direct-Acting Antiviral Agent | Shortened Duration Therapy | Clinical Trial | Comparison | PROTEASE INHIBITOR GS-9857 | SIMEPREVIR PLUS SOFOSBUVIR | COMBINATION | CHALLENGES | GENOTYPE 1 | TREATMENT-NAIVE | THERAPY | HEPATITIS-C VIRUS | CIRRHOSIS | DIRECT-ACTING ANTIVIRALS | GASTROENTEROLOGY & HEPATOLOGY | Humans | Middle Aged | Male | Carbamates - administration & dosage | Young Adult | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Sofosbuvir - adverse effects | Drug Therapy, Combination | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Macrocyclic Compounds - therapeutic use | Sofosbuvir - administration & dosage | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Carbamates - therapeutic use | Sulfonamides - administration & dosage | Medical colleges | Care and treatment | Protease inhibitors | Proteases | Transplantation of organs, tissues, etc | Product development | Hepatitis C virus | Hepatitis C | Health aspects | Analysis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1973 - 1982
In patients with HCV genotype 1 infection and cirrhosis, the rate of sustained virologic response was 92% with three new antiviral agents plus ribavirin for 12... 
SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | UNITED-STATES | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | TELAPREVIR | THERAPY | GENOTYPE 1 INFECTION | BOCEPREVIR | HCV INFECTION | EPIDEMIOLOGY | Recurrence | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Hepatitis C, Chronic - complications | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Logistic Models | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Complications and side effects | Evaluation | Care and treatment | Usage | Hepatitis C | Liver cirrhosis | Ribavirin | Headache | Antiviral agents | Ritonavir | Body weight | Fatigue | Infections | Nausea | Proteinase inhibitors | RNA polymerase | Patients | Cirrhosis | Liver cancer | Genotype & phenotype | Hepatitis | Hemoglobin | Interferon | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus | Cirrosi hepàtica | Inhibidors enzimàtics | Enzyme inhibitors | Hepatic cirrhosis
Journal Article
JAMA, ISSN 0098-7484, 03/2015, Volume 313, Issue 12, pp. 1223 - 1231
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1983 - 1992
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 11/2016, Volume 44, Issue 9, pp. 946 - 956
Journal Article